Merck acquires start-up biotech for $1.1 billion

Share this article:
Merck entered a deal to acquire biotech firm Sirna Therapeutics for $1.1 billion. The deal will give Merck access to a new class of medicines based on RNA interference (RNAi) technology. RNAi is a considered a powerful mechanism for inactivating particular genes and is used widely in laboratories to study genetic functions. Both Merck and Sirna are hoping the technique can be harnessed to kill viruses or tumors for instance by “turning off” their genes. “We believe that RNAi could significantly change the way in which we go about discovering and developing drugs, and could become a new way to treat patients with unmet medical needs,” said Merck research president Peter Kim in a statement.
Share this article:
close

Next Article in News

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.